文献速递骨质疏松与钙磷/甲状旁腺

唑来膦酸与安慰剂治疗儿童糖皮质激素性骨质疏松的随机双盲3期试验

Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

安慰剂组2例出现新发低创伤椎体骨折,唑来膦酸组无。不良事件多在首次输注后10天内发生,无死亡或治疗相关停药。

要点

  • 唑来膦酸0.05 mg/kg每6个月静脉输注可显著改善GIO患儿12个月LSBMDZ。
  • 不良事件多在首次输注后10天内发生,无治疗相关停药或死亡。

核心结论

  • 在儿童糖皮质激素性骨质疏松中,唑来膦酸较安慰剂显著提高12个月腰椎骨密度Z值。
  • 唑来膦酸组无新发低创伤椎体骨折,安慰剂组有2例。
  • 大多数不良事件发生在首次输注后10天内,无死亡或治疗相关停药。

研究设计与样本

  • 多国、随机、双盲、安慰剂对照3期试验(NCT00799266)。
  • 随机1:1分配接受每6个月静脉唑来膦酸0.05 mg/kg或静脉安慰剂。
  • 主要终点为基线至12个月腰椎骨密度Z值(LSBMDZ)变化。

主要发现

  • 唑来膦酸组LSBMDZ从-2.13±0.79升至-1.49±1.05,安慰剂组从-2.38±0.90降至-2.27±1.03。
  • 安慰剂组2例出现新发低创伤椎体骨折,唑来膦酸组无。
  • 不良事件:唑来膦酸组15/18例(83%),安慰剂组12/16例(75%),多在首次输注后10天内发生。

关键数值与推荐

  • 唑来膦酸用法:每6个月静脉输注0.05 mg/kg。

临床怎么用

  • 对于5至17岁糖皮质激素性骨质疏松患儿,可考虑每6个月静脉唑来膦酸0.05 mg/kg以改善腰椎骨密度。
  • 输注后10天内应关注不良事件,尤其是首次输注后。

局限性

  • 所有患儿均有低创伤椎体骨折,结果外推需谨慎。
  • 随访时间为12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucocorticoids (GCs) prescribed for chronic pediatric illnesses are associated with osteoporotic fractures. OBJECTIVE: This study aims to determine the efficacy and safety of intravenous (IV) zoledronic acid (ZA) compared with placebo to treat pediatric GC-induced osteoporosis (GIO). METHODS: Children aged 5 to 17 years with GIO were enrolled in this multinational, randomized, double-blind, placebo-controlled phase 3 trial (ClinicalTrials.gov NCT00799266). Eligible children were randomly assigned 1:1 to 6 monthly IV ZA 0.05 mg/kg or IV placebo. The primary end point was the change in lumbar spine bone mineral density z score (LSBMDZ) from baseline to month 12. Incident fractures and safety were assessed. RESULTS: Thirty-four children were enrolled (mean age 12.6 ± 3.4 years [18 on ZA, 16 on placebo]), all with low-trauma vertebral fractures (VFs). LSBMDZ increased from -2.13 ± 0.79 to -1.49 ± 1.05 on ZA, compared with -2.38 ± 0.90 to -2.27 ± 1.03 on placebo (least squares means difference 0.41 [95% CI, 0.02-0.81; P = .04]); when corrected for height z score, the least squares means difference in LBMDZ was 0.75 [95% CI, 0.27-1.22; P = .004]. Two children on placebo had new low-trauma VF vs none on ZA. Adverse events (AEs) were reported in 15 of 18 children (83%) on ZA, and in 12 of 16 (75%) on placebo, most frequently within 10 days after the first infusion. There were no deaths or treatment discontinuations due to treatment-emergent AEs. CONCLUSION: LSBMDZ increased significantly on ZA compared with placebo over 1 year in children with GIO. Most AEs occurred after the first infusion.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ward LM, Choudhury A, Alos N, et al. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. J Clin Endocrinol Metab. 2021. PMID: 34228102. doi:10.1210/clinem/dgab458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。